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 ABSTRACT 
 A randomized complete block design 
was used to compare the effects of feed-
ing melengestrol acetate (MGA) at 0.4 
(0.4M) and 0.5 (0.5M) mg/d per head 
on feedlot performance, estrus activity, 
and carcass characteristics of commer-
cial beef heifers (n = 1,418; 10 pens/
treatment). Within 48 h of arrival at 
the research site, heifers were assigned 
to treatment, processed according to 
feedlot protocol, and administered an 
abortifacient. After adaptation to a 95% 
concentrate diet, MGA was supplied at 
either 0.4 or 0.5 mg/head daily. Es-
trus activity was monitored twice daily 
and summarized as a count of heifers 
showing estrus within a pen over each 
21-d interval throughout the study. Dry 
matter intake, ADG, G:F, and all other 
carcass measurements were not different 
(P > 0.10) between treatments. Overall 
treatment effects were different only for 
estrus activity (P = 0.03; 3.2 vs. 2.1% 
for 0.4M and 0.5M, respectively) and 
tended to be different for the percentage 
of dark-cutting carcasses (P = 0.10; 3.0 
vs. 1.7% for 0.4M and 0.5M, respec-
tively). Results of this study showed little 
difference between treatment groups for 
performance and carcass characteristics 
of feedlot heifers. The decrease in estrus 
activity and percentage of dark-cutting 
carcasses, however, may suggest an eco-
nomic advantage of feeding a higher level 
of MGA to finishing heifers. 
 Key words:   beef cattle ,  carcass , 
 feedlot ,  heifer ,  melengestrol acetate , 
 performance 
 INTRODUCTION 
 Melengestrol acetate (MGA; Pfizer 
Animal Health, New York, NY) is 
an orally active progestogen that has 
been commercially available since 
1968 as a feed additive to improve 
feed utilization and growth rate, and 
to suppress expression of estrus in 
feedlot heifers (Bloss et al., 1966; 
O’Brien et al., 1968; Lauderdale, 
1983). However, current production 
scenarios including different nutrition 
strategies, implant strategies, feed ad-
ditives, marketing specifications, and 
cattle genotypes result in a different 
level of production expectation than 
for cattle produced a few decades ago. 
 To achieve optimal feed conversion 
and growth and the highest degree of 
estrus suppression from MGA, a dose 
level of 0.35 to 0.50 mg/d per heifer 
has been recommended (Bloss et al., 
1966; Zimbelman and Smith, 1966). 
Differences in performance associated 
with varying dosages of MGA within 
its recommended levels have not 
received much attention under current 
management practices. Therefore, the 
objective of this study was to com-
pare the effects of MGA supplied at 
0.4 versus 0.5 mg/d per heifer in the 
finishing ration on estrus activity, 
ADG, G:F, and carcass characteristics 
of finishing feedlot heifers. 
 MATERIALS AND METHODS 
 Animal Management 
 This study was conducted in a man-
ner consistent with applicable laws 
and regulations governing the humane 
care of animals. Heifers were observed 
at least once daily to ensure animals 
were healthy, and, if any abnormality 
was detected, to ensure prompt and 
adequate treatment by a qualified 
veterinarian. 
 Commercial feedlot heifers of mixed 
breeds (n = 1,418; 9 to 14 mo of age; 
initial BW = 290 ± 1.9 kg) were 
used in a randomized complete block 
design study conducted at a com-
mercial research facility near Syra-
© 2009 American Registry of Professional Animal Scientists
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cuse, Kansas (Bos Technica Research 
Services Inc.). Experimental blocks 
were composed of 2 pens based on 
location, with a total of 20 pens (10 
blocks). Heifers were housed in dirt 
pens that were 21.3 × 91.4 m in size, 
with individual pen flow water tanks 
(1 × 3.7 m) and 19.5 linear meters of 
fence-line bunk space per pen. Cattle 
were processed by arrival date (March 
5 through March 28, 2007) and ran-
domly assigned 10 head at a time to 
pens within an experimental block 
until the desired head count in each 
pen was attained (70 to 75 heifers/
pen). Each block consisted of 2 pens 
randomly assigned to 1 of 2 MGA 
dose levels: 0.4 (0.4M) or 0.5 (0.5M) 
mg/d per head.
Based on evaluation of heifers upon 
arrival, cattle were excluded from 
the study if they required therapy for 
any injury or nonrespiratory disease, 
exhibited clinical signs of bovine 
respiratory disease, exhibited condi-
tions that could have affected their 
response to bovine respiratory disease 
treatments, were noticeably pregnant, 
or were bulls or steers. At the begin-
ning of the study, there were 709 
cattle in each treatment. Five steers 
were identified (n = 3 in the 0.4M 
group, and n = 2 in the 0.5M group) 
and removed from the study after 
initial enrollment. One heifer was 
killed because of injury, and 6 heifers 
died as a result of digestive problems 
(bloat). A total of 5 additional heifers 
were rejected from the study shortly 
after enrollment for chronic respira-
tory problems, founder, abscesses, or 
mechanical problems. Heifers com-
pleting the study were slaughtered 
at a commercial beef-packing facility 
(National Beef, Liberal, KS).
Within 48 h after allotment to the 
research pens, heifers were processed 
and received a unique identification 
number and tag with both a visual 
drop-down tag and an electronic tag 
in the left ear. For each heifer, pen 
number, date of enrollment, identifica-
tion number, and BW were recorded. 
Heifers were vaccinated upon arrival 
for viral (Bovi-Shield Gold 5, Pfizer 
Animal Health) and clostridial (Ultra 
Bac 7, Pfizer Animal Health) diseases 
and were treated for parasites (Du-
rasect II and Dectomax Injectable, 
Pfizer Animal Health). An abortifa-
cient (Lutalyse, Pfizer Animal Health) 
was administered to all heifers. Each 
heifer was implanted with 8 mg estra-
diol and 80 mg of trenbolone acetate 
(Revalor-IH, Intervet Inc., Millsboro, 
DE) in the right ear. Heifers were 
reimplanted with 200 mg trenbolone 
acetate (Finaplix-H, Intervet Inc.) 
in the left ear at either 105 (blocks 1 
through 5) or 112 (blocks 6 through 
10) d before slaughter.
Diet and Feeding
Diets were formulated to meet or 
exceed NRC (1996) requirements 
and fed for ad libitum consump-
tion. Heifers were adjusted to a 95% 
concentrate final diet using a series of 
3 step-up diets, with MGA included 
only in the final diet (Table 1). Heif-
ers were adjusted to the finishing 
diet within 5 wk after arrival. Feed 
additives included tylosin at 90 mg/d 
per head (Tylan, Elanco Animal 
Health, Greenfield, IN) and monensin 
(36 g/ton; Rumensin, Elanco Animal 
Health). Treatment doses of MGA 
(MGA 200, Pfizer Animal Health) 
were included at 0.4 or 0.5 mg/d 
per head. Ractopamine hydrochlo-
ride (200 mg/d per head; Optaflexx, 
Elanco Animal Health) was included 
in the diets of all heifers 28 d before 
slaughter. All microingredients were 
hand-weighed on analytical platform 
scales (Model ALC 2100.2, Acculab, 
Bradford, MA) to the nearest 0.01 g 
before their addition to the ration. 
Additives were placed in a flush bowl 
and mixed with approximately 20 L 
of water for 45 s. Diets were sampled 
daily and analyzed for DM content, 
and weekly composites of the daily 
samples were analyzed for nutrient 
content (SDK Laboratory, Hutchin-
son, KS) and monensin concentrations 
(Eurofins Laboratory, Memphis, TN). 
Cattle were fed 3 times daily and the 
amount of feed delivered to each pen 
was recorded for each feeding. Feed 
weigh-backs were recorded for each 
pen as needed throughout the study. 
Weighed-back feed was determined on 
a DM basis using a laboratory convec-
tion oven on site. Total feed intake 
per pen was calculated on a DM basis 
as the amount of feed offered minus 
the weighed-back portion of feed. 
Daily feed intake was then calculated 
as total feed intake divided by total 
animal days, where total animal days 
was equal to the number of days each 
heifer was in its home pen from start 
to finish of the study, totaled for each 
pen.
Daily Observations
Daily observations of abnormal 
conditions (morbidity, mortality, and 
adverse reactions) were performed 
by trained personnel. Animals that 
required treatment were taken from 
their pens, treated, and returned to 
their home pens according to stan-
dard feedlot therapy. Animals that 
either died or were killed underwent 
necropsy by a qualified veterinarian to 
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Table 1. Nutrient composition 
of experimental diet (DM basis) 
Item
Treatment1
0.4M 0.5M
Ingredient, %   
 Flaked corn 84.5 84.5
 Alfalfa hay 5.1 5.1
 Choice white grease 4.2 4.2
 Supplement2 6.2 6.2
Analyzed nutrient 
composition, %
  
 DM 80.69 80.55
 CP 12.69 12.78
 NPN 2.50 2.56
 Crude fiber 4.18 4.24
 Fat 7.51 7.64
 Ca 0.71 0.72
 P 0.27 0.28
1Treatments: 0.4M = 0.4 mg of 
melengestrol acetate per head daily; 
0.5M = 0.5 mg of melengestrol 
acetate per head daily.
2Supplement contained at least 74% 
CP and not more than 44% NPN. All 
diets contained tylosin at 90 mg/d per 
head (Tylan, Elanco Animal Health, 
Greenfield, IN) and 36 g/ton of 
monensin (Rumensin, Elanco Animal 
Health).
assess the cause of death. For heifers 
removed from the study, a qualified 
veterinarian diagnosed the cause of 
removal.
Estrus detection observations were 
conducted twice daily (morning and 
afternoon) for approximately 10 min 
by trained personnel. Frequency of es-
trus activity was recorded while heif-
ers were fed the finishing diet. Estrus 
was determined by heifers exhibiting 
standing heat. Observed estrus activ-
ity was recorded on a daily basis as 
the total number of heifers exhibiting 
standing estrus within a pen during 
each observation.
Live Performance
Pen BW was recorded at process-
ing and just before slaughter. Initial 
BW was calculated as the pen BW 
at processing divided by the number 
of heifers placed. Final shrunk BW 
was calculated as the pen BW before 
slaughter × 0.96 divided by the num-
ber of heifers shipped for slaughter. 
An adjustment of 4% was applied to 
final pen BW to account for shrink 
associated with rumen fill. Total pen 
BW gain was calculated as the dif-
ferences between final and initial BW 
and daily BW gain was calculated as 
total BW gain divided by the average 
number of days on feed.
Carcass Characteristics
Heifers were slaughtered by block 
on 1 of 2 d (September 4 or 17, 2007). 
All heifers within a block were slaugh-
tered on the same day. Average days 
on feed was 176 and ranged from 166 
to 182. Carcass data were collected 
at the time of slaughter by USDA 
meat graders and an independent 
carcass collection team (Cattle Trail 
Inc., Johnson, KS). Carcass measures 
included hot carcass weight, dressing 
percentage, 12th-rib fat thickness, LM 
area, marbling score, USDA QG and 
YG, liver abscess incidence, KPH, 
empty body fat percentage, cutability 
percentage, and presence of dark-
cutting carcasses within a pen. Liver 
abscesses were scored according to 
the 3-point scale described by Elanco 
(1974).
Statistical Analysis
The response variables of interest 
were initial and final BW, ADG, total 
BW gain, DMI, G:F, estrus activity, 
and carcass variables. Pen was the 
experimental unit for all variables. 
Mixed model procedures (SAS Insti-
tute Inc., Cary, NC) were used that 
included the random effects of block, 
the fixed effects of treatment, and 
treatment × block as the error term. 
Tests of treatment differences were 
based on least significant differences. 
Carcass measures that were cat-
egorically expressed included USDA 
QG and YG, liver abscesses, and 
dark-cutting carcasses. The response 
variables for categorically expressed 
carcass measures were evaluated as 
proportional carcass measures within 
pen and were analyzed using the 
GLIMMIX procedure (SAS Institute 
Inc.) with the same mixed model 
described above. Treatment differ-
ences for carcass quality and YG were 
based on the percentage of carcasses 
within a pen that graded Choice or 
better and had a YG of less than 
4, respectively. Estrus activity was 
evaluated daily throughout the study 
and was divided into 21-d intervals 
for statistical evaluation. The total 
number of heifers within a pen that 
were observed showing standing heat 
in each 21-d interval was calculated 
and the totals were analyzed with a 
repeated-measures generalized mixed 
model that included the fixed effects 
of treatment, period of study (21-d 
interval), and the treatment × period 
of study interaction and the random 
effects of block, the block × treatment 
interaction, and residual error. All 
generalized mixed model procedures 
assumed a logit link function and a 
binomial distribution, and estimates 
of least significant differences and 
SE were back-transformed to their 
observed scale.
RESULTS AND DISCUSSION
Results of heifer growth perfor-
mance and feed consumption are 
presented in Table 2 for each treat-
ment group. Body weights were simi-
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Table 2. Performance and estrus activity of heifers fed different levels 
of melengestrol acetate 
Item
Treatment1
SE2 P-value0.4M 0.5M
Pens 10 10 — —
No. of animals 709 709 — —
No. of animals removed 5 5 — —
No. dead 2 5 — —
Live performance
 Initial BW, kg 290 290 1.88 0.97
 DMI, kg 7.30 7.32 0.06 0.68
 Final BW,3 kg 524 524 1.88 0.92
 Total BW gain, kg 234 233 2.53 0.97
 ADG, kg 1.33 1.33 0.01 0.97
 G:F 0.18 0.18 0.01 0.64
Observed estrus activity,4 % 3.2 (0.42) 2.1 (0.32) — 0.03
1Treatments: 0.4M = 0.4 mg of melengestrol acetate per head daily; 0.5M = 0.5 mg of 
melengestrol acetate per head daily.
2SE = standard errors from mixed model analysis.
3Final BW was shrunk (applied a 4% pencil shrink on actual BW).
4Observed estrus activity least squares estimates were calculated from a generalized 
mixed model analysis and represent the percentage of heifers showing visual signs 
of estrus across all 21-d periods. Estimates of SE for each treatment are listed in 
parentheses.
lar between the 2 treatment groups, 
with initial and final BW means of 
290 and 524 kg, respectively, for the 
0.4M and 0.5M groups. Differences 
between 0.4M and 0.5M heifers were 
not present (P > 0.10) for DMI, total 
BW gain, ADG, or G:F. Removing 
dead and rejected calves from the 
analysis of performance did not influ-
ence performance results; therefore, 
results without the dead or rejected 
calves are not reported. Observa-
tion of estrus activity throughout the 
study revealed a higher frequency of 
heifers showing estrus (standing heat) 
in 0.4M (3.2%) compared with 0.5M 
(2.1%; P = 0.03) across all 21-d peri-
ods such that the treatment × period 
interaction was not significant (P = 
0.83).
The effect of different dosages of 
MGA on heifer performance and 
estrus suppression were evaluated 
during the early years of MGA de-
velopment (Zimbelman and Smith, 
1966; Young et al., 1969). Although 
the labeled dosage range for MGA is 
0.25 to 0.50 mg/d per head (US Food 
and Drug Administration, 1968), 
studies from Bloss et al. (1966) and 
Zimbelman and Smith (1966) sug-
gest a more refined level of 0.35 to 
0.50 mg/d per head for the optimal 
response in growth, feed efficiency, 
and estrus suppression. Results of 
this study showed little difference 
between treatment groups for growth, 
feed utilization, and carcass charac-
teristics, which agrees with previous 
data that showed little distinction in 
performance at MGA levels between 
0.35 and 0.50 mg/d per head (Bloss 
et al., 1966; Zimbelman and Smith, 
1966). The use of MGA in finishing 
diets may improve heifer performance 
by enhancing feed utilization through 
optimizing hormonal mechanisms 
that inhibit the preovulatory surge 
of luteinizing hormone, which pre-
vents ovulation of dominate follicles 
(Imwalle et al., 2002). Purchas et al. 
(1971) concluded that higher levels of 
estrogen in heifers treated with MGA 
plays a role in growth stimulation. 
However, in an earlier study, Purchas 
et al. (1970) suggested MGA stimu-
lates growth through suppressed adre-
nal cortical activity. Likewise, Moseley 
et al. (2003) showed a response to 
growth in MGA-treated steers (0.1 
mg/d) with increased fat deposition 
and decreased LM area, indicating 
that part of the effects of MGA may 
involve a nonfollicular mechanism. 
Results of the current study indicate 
that any mechanisms by which MGA 
acts on growth, feed conversion, or 
carcass characteristics are not sensi-
tive to dose variations between 0.4 
and 0.5 mg/d.
A major benefit of feeding MGA to 
feedlot heifers is through the sup-
pression of estrus. Heifers expressing 
physical signs of estrus show increased 
physical activity (increased pedal ac-
tivity and mounting) and physiologi-
cal stress associated with recurring 
ovulation. Early titration studies of 
MGA indicated the minimum effec-
tive dose to inhibit ovulation in most 
cattle was 0.42 mg, with complete 
suppression of ovulation occurring 
with a daily dose of 0.50 mg (Zimbel-
man and Smith, 1966). Young et al. 
(1969) also showed a minimum dose 
for optimal suppression of estrus of 
0.4 mg/d in Angus heifers. Young et 
al. (1969) fed MGA at a dose of 0.0, 
0.2, 0.4, and 0.6 mg/d per calf for 154 
d and reported at least one incidence 
of observed estrus in 95.0, 70.6, 15.0, 
and 0.0% of the heifers, respectively, 
for each dose. In the current study, 
estrus activity was suppressed in both 
0.4M and 0.5M groups when com-
pared with negative controls of previ-
ous studies (Zimbelman and Smith, 
1966; Young et al., 1969), with fewer 
incidences of estrus associated with 
the 0.5M group. In the present study, 
a lower frequency of observed estrus 
at the 0.4-mg dose was observed com-
pared with the results of Young et al. 
(1969).
Heifers fed MGA for an extended 
period of time are expected to re-
turn to estrus approximately 3 to 7 d 
after MGA withdrawal (Zimbelman 
and Smith, 1966; Roussel and Be-
atty, 1969; Wettemann et al., 1973). 
However, the effects of temporary 
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Table 3. Carcass performance of heifers fed different levels of 
melengestrol acetate 
Item
Treatment1
SE P-value0.4M 0.5M
Carcass measure
 Dressing percentage 65.1 65.0 0.09 0.21
 Hot carcass weight, kg 341 340 1.44 0.59
 Marbling score2 299 298 3.13 0.92
 12th-rib fat thickness, cm 1.29 1.32 0.03 0.29
 KPH, % 2.24 2.20 0.03 0.10
 LM area, cm2 91.2 90.2 0.48 0.10
 Calculated YG 2.56 2.64 0.05 0.13
 Empty body fat, % 26.7 26.9 0.18 0.19
 Cutability, % 50.8 50.6 0.11 0.13
Proportional carcass measure3
 Dark-cutting carcasses, % 3.0 (1.10) 1.7 (0.68) — 0.10
 QG Prime and Choice, % 37.9 (2.08) 37.3 (2.07) — 0.84
 YG 1, 2, or 3, % 82.9 (2.46) 85.4 (2.22) — 0.24
 Abscessed livers, % 6.4 (1.14) 8.4 (1.37) — 0.18
1Treatments: 0.4M = 0.4 mg of melengestrol acetate/head daily; 0.5M = 0.5 mg of 
melengestrol acetate/head daily.
2300 = Slight0; 400 = Small0; 500 = Modest0.
3Treatment least squares means for proportional carcass measures were calculated 
from a generalized linear mixed model analysis. Estimates of SE for each treatment 
are listed in parentheses.
intervals of reduced MGA intake on 
ovulation are unclear. Young et al. 
(1969) speculated that heifers broke 
through the estrus suppression ef-
fects of MGA and ovulated because 
of inconsistent consumption of MGA 
throughout the feeding interval of 
their field trial. It was suggested that 
maximum estrus suppression required 
heifers not to miss a single MGA feed-
ing. In the presence of an antagonistic 
relationship between daily feed intake 
variability and estrus suppression in 
MGA-fed heifers, we might expect to 
see more estrus activity in groups fed 
at a lower MGA doses. In the cur-
rent study, daily feed intake was not 
recorded for individual animals, and 
results reported herein do not validate 
this relationship between feed intake 
variation and estrus suppression.
Overall carcass performance did not 
vary with MGA dose level (P > 0.10), 
with the exception of dark-cutting 
carcasses. Distributions of carcass 
USDA QG and YG as well as liver 
abscesses are presented in Tables 3 
and 4. Carcass quality was consistent 
between the 2 treatment groups, with 
the percentage of carcasses grading 
Choice or better within a pen ranging 
from 31.4 to 48.6% and 31.1 to 55.7% 
for 0.4M and 0.5M, respectively (data 
not shown). Distributions of YG were 
also similar, with the percentage of 
carcasses having a YG <4 ranging 
from 64.3 to 91.4% and 67.6 to 91.8% 
for 0.4M and 0.5M, respectively (data 
not shown). There was a trend (P 
= 0.10) for 0.4M heifers to exhibit a 
greater number of dark-cutting car-
casses (3.0%) compared with 0.05M 
heifers (1.7%). Estimated mean values 
for calculated YG resulted in 0.09 YG 
units higher for 0.5M; however, this 
difference was not significant (P = 
0.13).
Bloss et al. (1966) and Lauder-
dale (1983) reported no difference 
in carcass characteristics in heifers 
fed different MGA dose levels, which 
is in agreement with data from the 
present study. Others, however, have 
reported increases in external fat 
deposition, reduced LM area (Mader 
and Lechtenberg, 2000), or greater 
marbling scores (Macken et al., 2003; 
Kreikemeier and Mader, 2004) in 
MGA-fed heifers compared with heif-
ers not fed MGA. The National Beef 
Quality Audit-2000 (McKenna et al., 
2002) reported 2.3% dark-cutting 
beef carcasses in the US market. 
Differences in the frequency of dark-
cutting carcasses in this study only 
approached significance (3.0 and 1.7% 
for 0.4M and 0.5M, respectively; P = 
0.09), but the differences do support 
an economic advantage for 0.5M heif-
ers. Based on grid-pricing markets 
reported by the USDA (2008), the av-
erage discount placed on dark-cutting 
carcasses was $0.6486/kg of carcass 
weight (range of $0.3307 to $1.21). 
For this example ($0.6486) and results 
reported herein, the differences in car-
cass value for a pen of 100 heifers fed 
at the 0.4M versus 0.5M dose, both 
with a hot carcass average weight of 
340 kg, would be $311.98 more for the 
0.5M group [100 heifers × (1.7% × 
340 kg × $0.6486) − (3.0% × 340 kg 
× $0.6486) = −$311.98].
The relationships between dark-cut-
ting carcasses and environmental fac-
tors (management, season, sex) have 
been documented (Kreikemeier et al., 
1998; Scanga et al., 1998). However, 
the link between dark-cutting carcass-
es and heifer estrus is not clear. Scan-
ga et al. (1998) evaluated commercial 
cattle over a 3-yr period (n = 11,663 
pens of steers, n = 3,645 pens of 
heifers) and reported sex as having a 
significant effect on dark-cutting beef, 
with heifers averaging 0.3% more dark 
cutters per pen than steers (0.08% vs. 
0.38% ± 0.001) for steers and heifers, 
respectively, throughout the study). 
Voisinet et al. (1997) indicated heifers 
were more excitable than older parous 
females. Kenny and Tarrant (1988) 
reported a negative relationship 
between muscle glycogen and estrus 
activity in heifers. Decreased muscle 
glycogen inhibits the reduction of 
muscle pH and results in dark-cutting 
beef (Ashmore et al., 1973). Romans 
et al. (1988) showed heifers slaugh-
tered during estrus tended to have 
darker cutting carcasses. The causal 
effects of these relationships have yet 
to be determined.
IMPLICATIONS
There have been numerous changes 
in the feedlot industry since MGA 
was first introduced in 1968. These 
include grain processing, breed type, 
mature BW, implant regimen, adap-
tation strategies, and dietary en-
ergy concentration. Despite all these 
changes, MGA appears to perform 
efficiently on a feedlot performance 
basis at the same FDA-approved lev-
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Table 4. Descriptive summary 
of carcass USDA QG and YG 
categories and the proportion 
of abscessed livers of 
heifers fed different levels of 
melengestrol acetate 
Item
Treatment1
0.4M 0.5M
Carcass 702 699
QG distribution,2 %
 Prime 0.4 0.4
 Choice 37.5 36.9
 Select 55.5 58.5
 Other 6.6 4.2
YG distribution,2 %
 YG 1 7.5 7.0
 YG 2 33.8 29.9
 YG 3 41.0 47.9
 YG 4 15.2 12.6
 YG 5 2.4 2.6
Liver abscesses 
score,3 %
 0 93.5 91.5
 1 4.7 7.0
 2 0.5 0.4
 3 1.3 1.1
1Treatments: 0.4M = 0.4 mg of 
melengestrol acetate per head daily; 
0.5M = 0.5 mg of melengestrol 
acetate per head daily.
2USDA grades were assigned by 
USDA graders as reported by the 
packing plant; distributions represent 
the percentage of carcasses 
assigned a given grade.
3Abscess scoring system (Elanco, 
1974): 0 = healthy liver; 1 = 1 to 4 
small abscesses; 2 = 1 to 4 medium 
abscesses; and 3 = 1 or more large 
abscesses.
els as when initially approved for use 
in 1968. Feeding MGA at the high-
est labeled dose may be economically 
beneficial in reducing the frequency 
of estrus activity and any associated 
dark-cutting carcasses within a group 
of heifers. However, variations in daily 
individual heifer feed intake need to 
be evaluated further to determine its 
influence on breaks in estrus suppres-
sion and dark-cutting carcasses in 
heifers fed at lower MGA doses.
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